Human Metabolome Technologies, Inc. (6090) Stock Price

Human Metabolome Technologies is a company that specializes in comprehensive analysis of metabolites (metabolic compounds) and provides contract analysis services along with solutions based on analysis results. The company supports the understanding of life phenomena and functional evaluation of materials and products through high-sensitivity metabolome analysis.

The company's primary customers include pharmaceutical companies, universities and public research institutions, food and material manufacturers, and companies engaged in bio-manufacturing. Revenue is primarily generated from contract analysis fees and the sale of consulting services and development support packages based on analysis results, with small-scale clinical trials and proprietary prediction services serving as additional revenue sources.

The business operates as a single integrated entity with services divided into three main areas. Life science research support assists in biomarker discovery and elucidation of mechanisms of action. Functional material development support provides one-stop assistance from ingredient discovery through targeted clinical trials to health claim prediction. Bio-manufacturing support analyzes cultivation processes and proposes productivity improvement strategies, contributing to manufacturing efficiency.

The company has set "Building Growth Foundations" as its medium-term management strategy for fiscal years 2024–2026, targeting consolidated net sales of 1.6 billion yen and consolidated operating profit of 300 million yen by June 2026, the final year of the plan. The company has achieved 12 consecutive years of revenue growth, and in the previous fiscal year, operating profit increased 13.3% year-over-year, demonstrating steady profit improvement. The company aims to maintain and accelerate this momentum.

Priority investment areas are three pillars: life science research support, functional material development support, and bio-manufacturing support. Notably, bio-manufacturing support, which began in July 2025, has demonstrated productivity improvements and differentiates itself by providing integrated production process analysis and improvement proposals to corporate clients. The company is strengthening its revenue model by combining consulting based on contract analysis and development support packages to meet the needs of corporate customers in pharmaceuticals, food, and materials manufacturing.

For new market development and business expansion, the company is pursuing stable growth of existing services alongside early-stage launches of new services, anticipating growth in domestic and international biotech markets. From June 2026, business segments will be consolidated into three pillars—life science research support, functional material support, and bio-manufacturing support—enabling flexible resource allocation to accelerate sales expansion in the corporate sector and new business creation. Additionally, the company plans to diversify its customer base by addressing overseas demand.

Regarding technological innovation, the company is advancing its core high-sensitivity metabolome analysis technology while implementing concrete measures to expand analytical capacity and improve productivity. The company is promoting production management system implementation at its Tsuruoka headquarters, automation through robotics, development of high-speed analytical methods, and labor reduction through AI application in analytical processes to shorten analysis time and reduce costs. In parallel, the company is strengthening information security and risk management systems while investing in employee capability development to enhance new business creation capacity.